-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On June 15th, CStone Pharmaceuticals announced that it would cooperate with Pfizer on ROS1-positive advanced non-small cell lung cancer (NSCLC) in Greater China to jointly develop lorlatinib
.
This upcoming clinical study of ROS1-positive lung cancer in China is the world's first key study of loratinib on this target
.
In recent years, the incidence of lung cancer in China has continued to increase
.
According to the latest global cancer burden data in 2020, there will be approximately 820,000 new lung cancer cases in China in 2020, and approximately 710,000 lung cancer deaths
.
Loratinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) with central nervous system penetration
.
As early as November 2018, it was approved by the FDA for accelerated listing in the United States for the second-line treatment of ALK-positive metastatic NSCLC patients who have previously received crizotinib and at least one other ALK inhibitor
.
In clinical studies, loratinib has also shown preliminary efficacy and good safety for ROS1-positive advanced NSCLC
.
In a phase I/II study, loratinib improved the objective response rate (ORR) and intracranial ORR in patients with ROS1-positive advanced NSCLC who were initially treated with TKI drugs or failed ROS1 inhibitor treatment
.
Last year, CStone Pharmaceuticals and Pfizer reached a strategic cooperation, including Pfizer’s US$200 million equity investment in CStone Pharmaceuticals, CStone’s authorization of Pfizer to develop and commercialize suggliumab in mainland China, and CStone Pharmaceuticals Introduce more oncology products into the framework of cooperation with Pfizer in the Greater China region
.
CStone Pharmaceuticals and Pfizer will jointly select oncology products in the Pfizer pipeline that are in the late stage of research and development (that have passed the proof-of-concept) and jointly develop them in the Greater China region.
CStone and Pfizer can also optionally cooperate in the Greater China region.
Note: The original text has been deleted
